ENDRA Life Sciences Inc. (NDRA)

ENDRA Life Sciences Inc. (NDRA) Healthcare & Pipeline Overview

ENDRA Life Sciences Inc. develops thermo-acoustic enhanced ultrasound (TAEUS) technology, seeking to improve diagnostic capabilities, particularly for nonalcoholic fatty liver disease (NAFLD). Their focus on enhancing existing ultrasound platforms offers a potentially cost-effective alternative to traditional imaging modalities like MRI and CT scans within the medical diagnostics sector.

What Is the Investment Thesis for NDRA?

ENDRA Life Sciences Inc. presents a focused investment opportunity within the medical diagnostics space, primarily driven by its thermo-acoustic enhanced ultrasound (TAEUS) technology. The company's emphasis on nonalcoholic fatty liver disease (NAFLD) positions it within a market with significant unmet needs. The TAEUS technology aims to provide a cost-effective and accessible alternative to traditional imaging techniques like MRI, potentially disrupting the diagnostic landscape. Key value drivers include successful commercialization of the TAEUS system, expansion into other clinical applications beyond NAFLD, and strategic partnerships. The company's small market capitalization and limited financial resources pose risks, requiring careful monitoring of cash burn and fundraising activities. The negative Beta of -0.11 suggests low correlation with the overall market. Upcoming regulatory approvals and clinical trial results will serve as major catalysts. The P/E ratio of -0.32 reflects the company's current lack of profitability.

Based on FMP financials and quantitative analysis

NDRA Key Highlights

• ENDRA Life Sciences Inc. is focused on thermo-acoustic enhanced ultrasound (TAEUS) technology for improved diagnostic imaging.
• The company's primary target is the nonalcoholic fatty liver disease (NAFLD) market, addressing a significant unmet need.
• ENDRA aims to offer a cost-effective alternative to MRI and CT scans for liver fat assessment.
• A collaborative research agreement with General Electric Company could provide access to broader market opportunities.
• The company's market capitalization is $0.00B, indicating its early-stage growth potential and associated risks.

Who Are NDRA's Competitors?

NDRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NDRA's Key Strengths?

• Proprietary TAEUS technology.
• Focus on NAFLD diagnostics.
• Collaborative research agreement with GE.
• Potential for cost-effective alternative to MRI and CT.

What Are NDRA's Weaknesses?

• Limited financial resources.
• Small market capitalization.
• Early-stage commercialization.
• Dependence on regulatory approvals.

What Could Drive NDRA Stock Higher?

• Regulatory approvals for the TAEUS system in key markets.
• Results from ongoing clinical trials evaluating the efficacy of TAEUS for NAFLD diagnostics.
• Expansion of strategic partnerships and collaborations with medical device companies and healthcare providers.
• Increasing market awareness and adoption of TAEUS technology.

What Are the Key Risks for NDRA?

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Competition from established imaging modalities (MRI, CT) and other diagnostic technologies.
• Regulatory hurdles and reimbursement challenges for TAEUS technology.
• Limited financial resources and dependence on fundraising activities.
• Clinical trial failures or delays in product development.
• Negative Beta of -0.11 indicates potential sensitivity to market fluctuations.

What Are the Growth Opportunities for NDRA?

• Expansion into NAFLD Diagnostics: The increasing prevalence of NAFLD presents a significant growth opportunity for ENDRA. The global NAFLD market is projected to reach billions of dollars in the coming years. ENDRA's TAEUS technology aims to provide a non-invasive and cost-effective solution for early detection and monitoring of NAFLD, potentially capturing a substantial share of this growing market. Successful commercialization of the TAEUS system and positive clinical data will be crucial for penetrating this market. Timeline: Ongoing, with increasing market penetration expected over the next 3-5 years.
• Thermoablative Surgery Monitoring: ENDRA's TAEUS technology can be applied to temperature monitoring during thermoablative surgery, offering real-time feedback to surgeons. The market for surgical navigation and monitoring systems is expanding, driven by the demand for minimally invasive procedures and improved patient outcomes. Integrating TAEUS into thermoablation procedures could provide a valuable tool for precise temperature control and reduced risk of complications. Timeline: Development and clinical trials ongoing, with potential market entry in 3-5 years.
• Vascular Imaging Applications: TAEUS has the potential to enhance vascular imaging, providing improved visualization of blood vessels and blood flow. The market for vascular imaging is driven by the increasing prevalence of cardiovascular diseases and the need for accurate diagnosis and treatment planning. ENDRA's technology could offer a non-invasive alternative to traditional angiography, reducing patient risk and healthcare costs. Timeline: Research and development phase, with potential for clinical trials and market entry in 5+ years.
• Tissue Perfusion Assessment: Assessing tissue perfusion is crucial in various clinical settings, including wound healing, organ transplantation, and cancer treatment. ENDRA's TAEUS technology could provide a non-invasive method for monitoring tissue perfusion, enabling clinicians to make informed decisions about patient care. The market for perfusion monitoring devices is growing, driven by the demand for improved patient outcomes and reduced healthcare costs. Timeline: Research and development phase, with potential for clinical trials and market entry in 5+ years.
• Strategic Partnerships and Collaborations: ENDRA's collaborative research agreement with General Electric Company demonstrates the potential for strategic partnerships to accelerate technology development and market access. Collaborating with other medical device companies, research institutions, and healthcare providers could provide access to new markets, funding, and expertise. Building a strong network of partnerships will be essential for ENDRA's long-term growth and success. Timeline: Ongoing, with continuous efforts to establish and expand strategic partnerships.

What Opportunities Does NDRA Have?

• Expanding NAFLD market.
• Applications in thermoablative surgery monitoring.
• Potential for vascular imaging and tissue perfusion assessment.
• Strategic partnerships and collaborations.

What Threats Does NDRA Face?

• Competition from established imaging modalities (MRI, CT).
• Regulatory hurdles and reimbursement challenges.
• Technological advancements by competitors.
• Potential for clinical trial failures.

What Are NDRA's Competitive Advantages?

• Proprietary thermo-acoustic enhanced ultrasound (TAEUS) technology.
• Focus on a specific market niche (NAFLD diagnostics).
• Collaborative research agreement with General Electric Company.
• Potential for cost-effective alternative to MRI and CT scans.

What Does NDRA Do?

ENDRA Life Sciences Inc., founded in 2007 and based in Ann Arbor, Michigan, is a medical technology company focused on enhancing the capabilities of clinical diagnostic ultrasound. The company's core technology, thermo-acoustic enhanced ultrasound (TAEUS), is designed to improve the accuracy and functionality of ultrasound imaging. TAEUS works by transmitting sound waves that interact with tissues, organs, and blood within the body, providing detailed diagnostic information. ENDRA's initial focus is on addressing the growing global health concern of nonalcoholic fatty liver disease (NAFLD), which affects a significant portion of the population and often goes undiagnosed until advanced stages. Beyond NAFLD, ENDRA envisions TAEUS being utilized in various other applications, including temperature monitoring during thermoablative surgery, vascular imaging, and assessing tissue perfusion. The company also acknowledges the role of existing diagnostic imaging technologies like computed tomography (CT), magnetic resonance imaging (MRI), and traditional ultrasound in providing physicians with internal views of the body to aid in treatment and diagnosis of various medical conditions. ENDRA has a collaborative research agreement with General Electric Company, indicating potential for broader market reach and technological integration. ENDRA aims to offer a cost-effective and accessible alternative to more expensive imaging modalities.

What Products and Services Does NDRA Offer?

• Develop thermo-acoustic enhanced ultrasound (TAEUS) technology.
• Enhance the capabilities of clinical diagnostic ultrasound.
• Focus on nonalcoholic fatty liver disease (NAFLD) diagnostics.
• Offer a potential alternative to MRI and CT scans for liver fat assessment.
• Develop technology for temperature monitoring during thermoablative surgery.
• Explore applications in vascular imaging and tissue perfusion assessment.

How Does NDRA Make Money?

• Develop and commercialize TAEUS-based diagnostic imaging systems.
• Generate revenue through sales of TAEUS systems to hospitals and clinics.
• Potentially generate revenue through service contracts and software updates.
• Seek strategic partnerships and collaborations for technology development and market access.

What Industry Does NDRA Operate In?

ENDRA Life Sciences Inc. operates within the medical diagnostics industry, a sector characterized by continuous innovation and increasing demand for advanced imaging technologies. The market for non-invasive diagnostic tools for liver diseases, particularly NAFLD, is expanding due to the rising prevalence of obesity and related metabolic disorders. Competition includes established players offering MRI, CT, and traditional ultrasound solutions. ENDRA aims to differentiate itself through its TAEUS technology, which seeks to enhance the capabilities of existing ultrasound platforms and provide a more cost-effective alternative to expensive imaging modalities. The industry is also influenced by regulatory approvals, reimbursement policies, and technological advancements in areas like artificial intelligence and image processing.

Who Are NDRA's Key Customers?

• Hospitals and clinics seeking improved diagnostic imaging capabilities.
• Physicians specializing in liver disease and metabolic disorders.
• Researchers and scientists involved in clinical trials and medical research.
• Thermoablative surgeons

Net buyingInsider Activity

Over the past six months, ENDRA Life Sciences Inc. insiders filed 7 SEC Form 4 transactions — 0 sales and 7 purchases. On net that is roughly 316K shares acquired (about $0) — insiders putting money in tends to read as conviction.

NDRA Valuation & Market Position

With a $3.73M market cap, ENDRA Life Sciences Inc. sits in the micro-cap segment of the market. Relative to its peer group, NDRA's quantitative score of 27/100 is below the peer average of 64/100.

Key Financial Metrics

A current ratio of 0.64 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -118.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

ENDRA Life Sciences Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

FY2026 estForward Outlook

Wall Street analysts project ENDRA Life Sciences Inc. revenue of about $100K for fiscal 2026, with EPS near $-3.54.

Company Profile

ENDRA Life Sciences Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Ann Arbor, US. The company is led by CEO Alexander Y. Tokman. NDRA has traded publicly since 2017.

NDRA Financials

NDRA Latest News

NDRA Analyst Consensus

NDRA MoonshotScore

ENDRA Life Sciences Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources